Ovulation induction drug and ovarian cancer: an updated systematic review and meta-analysis

Yu, Liang; Sun, Jiafan; Wang, Qiqin; Yu, Wennian; Wang, Anqi; Zhu, Shu; Xu, Wei; Wang, Xiuli

doi:10.1186/s13048-022-01084-z

Cited by 7 publications

(1 citation statement)

References 101 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Previous studies have debated whether OI could increase the risk of invasive ovarian cancer (IOC) and borderline ovarian tumors (BOT). Although most studies have concluded that OI does not contribute to the risk of IOC and BOT, some scholars still proposed that OI may be associated with them (19).…”

Section: Discussionmentioning

confidence: 99%

Assessment of Different Neoplasias in the Adnexa Model Versus Risk of Malignancy Index as a Tool for Predicting Ovarian Malignancy in Postmenopausal Ovarian Cysts

ElMaraghy,

El-Shalakany,

Dwedar

et al. 2024

Preprint

View full text Add to dashboard Cite

Background Ovarian cancer is the most lethal gynecologic malignancy and every attempt should be made to develop screening programs to detect it at its early stages in order to improve survival rate. Using the ADNEX model in screening for ovarian cancer will help in triaging patients with adnexal masses before undergoing surgery which will help in optimizing outcomes particularly for those with ovarian malignancy. Patients & methods: This was a prospective study which included fifty postmenopausal patients with adnexal mass. All the included patients underwent ultrasound assessment of the adnexal mass and measurement of CA 125 level. Then, the data were collected to calculate the RMI, and integrated to IOTA ADNEX calculator. The primary outcome was determining the predictive accuracy of both RMI and ADNEX model for differentiating between benign and malignant ovarian tumors by setting both against the gold standard histopathology Results Out of the included 50 patients, 56% had benign ovarian lesions, 12% had borderline ovarian tumors, and 24% had malignant ovarian tumors. The Area under the receiver operating characteristic curve (AUC) for the RMI was 0.799 and with cutoff value of 115, the sensitivity was 81.8%, the specificity was 60.7% while the AUC was 0.864 for the ADNEX model and at 10% cutoff, the sensitivity was 91.1% and the specificity was 65%. Performance of the ADNEX for the five tumor types was highest when benign histopathology was compared as stage Ⅱ - Ⅳ malignant cases with AUC of 0.823. Conclusion ADNEX model is more sensitive than RMI for differentiating between benign and malignant tumors and it can be used as screening test. However, the application of ADNEX model needs significant experience in ultrasound evaluation of adnexal masses before it can be an integral part in the screening pathway of ovarian malignancy in postmenopausal patients with adnexal masses. Clinicaltrials.gov ID: NCT05755841 – Data of registration: 3/30/2024 “retrospectively registered”

show abstract

Section: Discussionmentioning

confidence: 99%

Assessment of Different Neoplasias in the Adnexa Model Versus Risk of Malignancy Index as a Tool for Predicting Ovarian Malignancy in Postmenopausal Ovarian Cysts

ElMaraghy,

El-Shalakany,

Dwedar

et al. 2024

Preprint

View full text Add to dashboard Cite

show abstract

Fertility treatment and risk of ovarian cancer in a large nationwide cohort of infertile Danish women

Jensen,

Guleria,

Albieri

et al. 2024

Intl Journal of Cancer

View full text Add to dashboard Cite

Whether fertility treatment increases the risk of ovarian cancer has been a concern for many decades, but previous research has yielded conflicting findings. We therefore investigated this association within a large population‐based cohort study of infertile women aged 20–45 years and living in Denmark between 1995 and 2017, as identified in the Danish Infertility Cohort (n = 146,110). The study cohort was linked to nationwide registers to obtain information on fertility drug use, cancer diagnoses, covariates, emigration, and vital status was. Hazard ratios (HR) and 95% confidence intervals (CI) with adjustment for potential confounders for ovarian cancer overall and for serous ovarian cancer were estimated using Cox proportional hazard models. During a median 10.3 years of follow‐up, 114 women were diagnosed with ovarian cancer of which 65 had serous ovarian cancer. Our results showed that the rate of serous ovarian cancer (HR 1.92; 95% CI 1.16–3.17) was increased after every use of progesterone but the association was not affected by increased follow‐up time since first use or with increased cumulative dose. We performed a secondary analysis adding less extensive data from 1971 through 1994 from the Danish Infertility Cohort. In this study cohort, 332 women developed ovarian cancer of which 192 had serous ovarian cancer. The overall results were similar, including the association between every use of progesterone and serous ovarian cancer (HR 2.05: 95% CI: 1.31–3.21). In conclusion, the novel finding that use of progesterone is associated with an increased rate of serous ovarian cancer warrants further investigation.

show abstract

Ovarian Stimulation and the Long-Term Risk of Cancer

Vassard,

Hunt,

Pinborg

et al. 2024

Reference Module in Biomedical Sciences

View full text Add to dashboard Cite

Ovulation induction drug and ovarian cancer: an updated systematic review and meta-analysis

Cited by 7 publications

References 101 publications

Assessment of Different Neoplasias in the Adnexa Model Versus Risk of Malignancy Index as a Tool for Predicting Ovarian Malignancy in Postmenopausal Ovarian Cysts

Assessment of Different Neoplasias in the Adnexa Model Versus Risk of Malignancy Index as a Tool for Predicting Ovarian Malignancy in Postmenopausal Ovarian Cysts

Fertility treatment and risk of ovarian cancer in a large nationwide cohort of infertile Danish women

Ovarian Stimulation and the Long-Term Risk of Cancer

Contact Info

Product

Resources

About